Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251118 | 0.94 | GPR35 (0.47) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4250257 | 0.92 | GPR35 (0.49) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4247593 | 0.92 | GPR35 (0.49) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4994397 | 0.92 | GPR35 (0.48) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4989412 | 0.88 | GPR35 (0.46) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4249890 | 0.88 | GPR35 (0.48) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4254261 | 0.87 | GPR35 (0.46) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4249962 | 0.87 | ACHE (0.55) | GPR35KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL4988821 | 0.84 | MEN1 (0.46) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4995314 | 0.80 | ATM (0.52) | GPR35KDM4EMEN1KMT2AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170851-A1 | Chroman Compounds | BERNSTEIN PETER | 2009-07-02 | — | — | US | disclosed |
| EP-1945624-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | Astra Zeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| WO-2007053095-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135442-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | GPR35 1756/4885KDM4E 2353/4885MEN1 214/4885 |
| US-20090170851-A1 | Chroman Compounds | CYP3A43, CYP2C9, CYP2C8 | GPR35 1814/4885KDM4E 2050/4885MEN1 268/4885 |
| US-20070185107-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | GPR35 1814/4885KDM4E 2050/4885MEN1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.